Stifel Financial’s Matinas BioPharma MTNB Stock Holding History

Stifel Financial’s Portfolio MTNB Stock Details MTNB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-1,620	Closed	-$63K	–	3384
2021 Q2	$63K	Hold	1,620	–	–	﹤0.01%	3267
2021 Q1	$85K	Buy	1,620 +557	+52%	+$37.4K	﹤0.01%	3134
2020 Q4	$72K	Sell	1,063 -41	-4%	-$1.9K	﹤0.01%	2963
2020 Q3	$42K	Buy	1,104 +400	+57%	+$15.9K	﹤0.01%	2817
2020 Q2	$27K	Sell	704 -83	-11%	-$3.18K	﹤0.01%	2796
2020 Q1	$24K	Buy	787 +87	+12%	+$5.25K	﹤0.01%	2718
2019 Q4	$78K	Buy	+700	New	+$40.6K	﹤0.01%	2903

Other funds holding MTNB

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

SIG

Sargent Investment Group Bethesda, Maryland $759M AUM 28.58% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

CCM

Courage Capital Management Nashville, Tennessee $70.6M AUM 13.29% 1-Year Est. Return

AWA

Arkadios Wealth Advisors Atlanta, Georgia $6.13B AUM 23.41% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

BCM

Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

JEST

JTC Employer Solutions Trustee St Helier, Jersey $1.2B AUM 37.55% 1-Year Est. Return

GCP

GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Stifel Financial's MTNB Position: Q3 2021 in Review

Stifel Financial sold out of Matinas BioPharma (MTNB) in Q3 2021, closing a stake of 1,620 shares — an estimated $63K sold.

Stifel Financial first reported a position in MTNB in Q4 2019 and held it in 7 quarters. The position peaked at $85K in Q1 2021. 67 funds tracked by Wall St. Rank hold MTNB as of Q3 2021.

Stifel Financial reported no remaining Matinas BioPharma position as of Q3 2021 after selling out during the quarter.
Stifel Financial sold 1,620 Matinas BioPharma shares in Q3 2021, an estimated $63K.
Stifel Financial first reported a position in Matinas BioPharma in Q4 2019 and held it in 7 quarters.
Stifel Financial's Matinas BioPharma position peaked at $85K in Q1 2021.
67 funds tracked by Wall St. Rank held Matinas BioPharma as of Q3 2021.

Based on Stifel Financial's 13F filing for Q3 2021, filed 15 Nov 2021.